ArticleClinics (Sao Paulo, Brazil)2026
Progesterone receptor variants and hormone therapy use in postmenopausal endometrial polyps: a case-control study.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate whether Progesterone Receptor (PGR) variants +331G/A (rs10895068) and V660L (rs1042838, a PROGINS proxy) are associated with Endometrial Polyps (EP) in postmenopausal women undergoing hysteroscopy.
methodsThis exploratory case-control study included 236 histopathologically confirmed EP cases and 73 hysteroscopy-negative controls from the same institution and period, unmatched. All eligible hysteroscopy-negative women during the study period were included, with no declinations. Genotyping of +331G/A and V660L was performed by PCR-HRM. Genetic comparisons used two-sided tests and multivariable logistic regression, with minimum detectable odds ratios estimated for 80% power at α = 0.05. Hormone Therapy (HT) and tamoxifen use were recorded as binary variables reflecting current use at hysteroscopy.
resultsGenotype distributions did not differ between groups for +331G/A (p = 0.245) or V660L (p = 0.435); call rates were 100% for both variants. Neither +331G/A nor V660L carrier status was significantly associated with EP after adjustment (aOR = 0.43, 95% CI 0.17-1.09, p = 0.074; and aOR = 0.59, 95% CI 0.31-1.11, p = 0.100, respectively). Current HT use was inversely associated with EP (aOR = 0.15, 95% CI 0.06-0.40; p < 0.001), though regimen data were unavailable. Genetic associations remained non-significant in the model excluding HT.
conclusionNeither PGR variant was significantly associated with EP. The sample could detect only relatively large effects, so smaller genetic associations cannot be excluded. The inverse association with binary HT exposure is hypothesis-generating rather than causal, given incomplete exposure characterization and the possibility of selection or residual confounding.
Indexed as
Identifiers
42880132What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.